



Long term results of pediatric heart transplantations: Single center experiences

Authors: Szymon Pawlak, Joanna Śliwka, Arkadiusz Wierzyk, Roman Przybylski, Jerzy Czapla, Bogusława Król, Piotr Przybyłowski

Article type: Original article

Received: May 2, 2022

Accepted: November 15, 2022

Early publication date: March 16, 2023

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Long term results of pediatric heart transplantations: Single center experiences

Short title: Pediatric heart transplantation program in Poland

Szymon Pawlak¹, Joanna Śliwka¹, Arkadiusz Wierzyk², Roman Przybylski³, Jerzy Czapla⁴, Bogusława Król⁵, Piotr Przybyłowski¹

¹Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Silesian Center for Heart Disease, Medical University of Silesia in Katowice, Zabrze, Poland

²Department of Cardiac Surgery, Transplantology and Mechanical Circulatory Support in Children, Silesian Center for Heart Diseases, Zabrze, Poland

³Department of Cardiac Transplantation and Mechanical Circulatory Support, Wrocław Medical University, Wrocław, Poland

⁴Department of Cardiac Anesthesiology and Intensive Care, Silesian Center for Heart Diseases, Zabrze, Poland

⁵Transplant coordinator in Silesian Center for Heart Disease, Zabrze, Poland

Correspondence to:

Szymon Pawlak, MD, PhD,

Department of Cardiac, Vascular and Endovascular Surgery and Transplantology,

School of Medicine with the Division of Dentistry in Zabrze,

Medical University of Silesia in Katowice,

Silesian Center for Heart Diseases,

Skłodowskiej-Curie 9, 41–800 Zabrze, Poland,

phone: +48 32 479 34 73,

e-mail: pawlaks@poczta.fm

ABSTRACT

Background: Heart failure (HF) is characterized by significant mortality in both adults and children. Characteristic of paediatric HF are feeding problems, poor weight gain, exercise intolerance or dyspnoea. These changes are often accompanied by endocrine disorders. The main causes of HF are congenital heart defects (CHD) cardiomyopathies, arrhythmias, myocarditis or heart failure secondary to oncological treatment. Heart transplantation (HTx) is the method of choice for treatment of end-stage HF in pediatric patients.

Aims: The aim is to summarize single center experience in heart transplantation in children.

Methods: Between 1988 and 2021 in the Silesian Center for Heart Diseases in Zabrze 122 pediatric cardiac transplantations were performed. In the group of recipients with failing Fontan circulation HTx was performed in 5 children. The study group was evaluated for postoperative course: rejection episodes depending on the medical treatment scheme, coinfections and mortality.

Results: 1-, 5- and 10-year survival rate between 1988 and 2001 were 53%, 53% and 50%, respectively. 1-, 5- and 10-year survival rate between 2002 and 2011 was 97%, 90% and 87%; between 2012 and 2021 1-year observation with survival rate 92%. The main cause of mortality both in early and in late period after transplantation was graft failure.

Conclusions: Cardiac transplantation in children remains the main method of treatment of end-stage heart failure. Our results at both early and long-term posttransplant period, are comparable to those obtained in the most experienced foreign centers.

Key words: cardiomyopathy, congenital heart defect, heart failure, paediatric heart transplantation

WHAT'S NEW?

This paper presents the summary of the unique pediatric heart transplant programme in Poland. Heart transplantation is the method of choice for treatment of end-stage heart failure in pediatric patients. This is rare pediatric procedure, related to high operational risk. The paper presents the valuable Polish operating and immunosuppression treatment protocol. The results obtained in the second and third periods are consistent with the data presented by leading centers in the world.

INTRODUCTION

Heart failure (HF) in children is a clinical and pathophysiological syndrome resulting from ventricular dysfunction and pressure or volume overload of the circulatory system. Characteristic for paediatric heart failure are feeding problems, poor weight gain, exercise intolerance or dyspnoea. These changes are often accompanied by changes in endocrine system. There is a complex aetiology of the HF in children. The main causes are congenital heart disease (CHD) and cardiomyopathies. Less frequent causes are cardiac arrhythmias and acquired heart diseases such as myocarditis, Kawasaki disease or heart failure secondary to oncological treatment. In the United States, 12 000 to 35 000 children suffer from heart failure

caused by CHD or cardiomyopathy. This gives an incidence of HF in the paediatric population of 16.4–48 cases per 100 000 children [1]. Each year, these patients require 14 000 hospitalizations, of which 65% are caused by CHD. According to Belgian observation, CHD accounts for about 50% of all hospitalizations due to exacerbation of HF. 14% of patients with single ventricle physiology require multiple hospitalizations due to HF exacerbations. Many of these patients will require mechanical circulatory support (MCS) or HTx qualifications in the future [2]. Cardiomyopathies occur with the frequency of 1.13–1.24 cases per 100 000 children. It is especially frequent in the group <1 year of age, where the prevalence of cardiomyopathy is estimated at 7.8–8.3 cases per 100 000 infants. Severe HF is also more common in this age group [3, 4]. Not all patients with cardiomyopathy will develop HF. The prevalence of HF in children with cardiomyopathy is estimated at 0.87 cases per 100 000 children under 16 years of age. 71% of HF episodes occur in patients with dilated cardiomyopathy (DCM) [5]. Heart transplantation (HTx) is considered as the method of choice for the treatment of end-stage HF in paediatric patients.

Historical overview

In 1960, Lower and Shumway [6] published the results of experiments with orthotopic cardiac transplantation in dogs using an oxygenator. They described the technique of preparation of the recipient and donor atrium (Shumway's technique), which is still but non in common use. On December 3, 1967, Christian Bernard of Groote Schuur Hospital in Cape Town (Republic of South Africa) performed the first successful heart transplant in human. Despite the use of advanced immunosuppression (local irradiation, azathioprine, prednisolone, actinomycin C) and the sanitary regime, patient died 18 days after the transplant due to infection caused by *Pseudomonas Pneumoniae* [7]. Three days later, on December 6, 1967, Adrian Kantrovitz of the Mamonides Medical Center in Brooklin (US) performed the first successful heart transplant in a child. Kantrovitz assumed that the underdevelopment of the immune system of the infant would facilitate surgery and subsequent treatment. The patient was a 3-week-old infant with critical CHD (tricuspid atresia type IA). The procedure was performed in deep hypothermia with full cardiac arrest. Due to post-transplant complications, the patient died after 6 hours [8].

Heart transplantation in the world

The introduction of effective and safe immunosuppressive drugs directly increased the number of successful transplants and extended the patients' survival time [9, 10]. According

to data from The International Society for Heart and Lung Transplantation (ISHLT) in 1982, 187 heart transplants were performed in the world, including 10 in children. In 1992, the number of transplanted hearts was 4 735, of which 406 were performed in children. This represented a 40-fold increase in the number of heart transplantations in children compared to the year 1982 in less than 10 years. 25% of transplanted pediatric patients were under one year old. According to data for 2021 the number of heart transplants in children from 1992 in total ranged from 458 to 663/year. With the increase in the transplants number the number of paediatric centers where this procedure is performed has also increased. Currently, there are 120 of them in the ISHLT database, of which 54% are located in North America (US and Canada). Indications for cardiac transplantation in children include three main types of diseases: myocardial disease like dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM) and arrhythmogenic ventricular cardiomyopathy (AVC); congenital heart defects (including hypoplastic left heart syndrome [HLHS]), Ebstein's anomaly, transpositions of the great arteries (TGA) and other diseases that impair the function of the heart, not belonging to the diseases mentioned above, such as myocarditis. Retransplantations account for 2%–3% of indications for HTx in children [11, 12]. The main indication for HTx in children under 1 year of age are CHD (53% of indications). In older age of pediatric recipients, this relation changes to cardiomyopathy, which accounts for 55% of indications in patients in the 11–17 age group [13]. The increase in the experience of transplantation teams and the improvement of immunosuppressive treatment noticeably influenced the survival time of the recipients. In the years 1982–1989, 1-, 5- and 10-year survival rate in the pediatric population was 63.7%, 57.2% and 51.6%, respectively. In the years 2004–2008 it increased to 81.8%, 70.8% and 66.2% respectively. In the years 2009–2015 the 1- and 5-year survival rate was 87.1%; and 80.0% respectively. The observed mean (standard deviation [SD]) survival time increased from 9.9 (6.9) years in 1982–1991 to 14.3 (3.4) years in the next decade. Mean survival time in the years 1982–2015 was: 22.3 years in the group of children <1 year of life, 18.4 years at the age of 1–5 years; 14.4 years at the age of 6–10 years and 13.1 years at the age of 11–17 years. Longer survival time occurs in patients who were transplanted due to cardiomyopathy compared to patients with congenital heart disease, regardless of the age at which HTx was performed [11]. The type of induction and immunosuppression as well as complications influenced the mean survival time. The most common complications after HTx are: primary graft failure, acute rejection, coronary artery disease (CAV), severe renal insufficiency or posttransplant lymphoproliferative disorder (PTLD). Early mortality during the first 30 days after transplantation is caused by

graft failure and corresponds to the 36.2% mortality. This often occurs in the group of children <5 year old, where it corresponds to the 45% mortality. The next causes are: stroke episodes (15.1%), multiple organ failure (11.2%), acute rejection of the transplanted heart (7.3%) and non-cytomegalovirus infections (6.5%). Between the 3rd to 5th and 5th to 10th year after HTx, the main cause of mortality is graft failure, corresponding to 36.4% and 40.5% mortality, respectively. The episode of acute rejection as well as increasing percentage of CAV are responsible for bad outcomes in those groups (15.3% and 11.7%, respectively) and also responsible for nearly 25% mortality among children 10 years after HTx [11].

Heart transplantation in Poland

The first Polish heart transplant was performed on April 1, 1969 by Jan Moll, Antoni Działkowiak and Kazimierz Rybiński at the S. Sterling Clinical Hospital in Łódź. Due to unrecognized pulmonary hypertension associated with heart failure, the recipient died shortly after surgery [14]. The development of the Polish heart transplant program is related to Zbigniew Religa, who on December 5, 1985, together with the team of the Provincial Cardiology Center in Zabrze (currently the Silesian Center for Heart Diseases in Zabrze), performed the first successful heart transplant in an adult in Poland. Three years later, on February 8, 1988, in the same Center, a team of cardiac surgeons under the leadership of Zbigniew Religa performed the first successful heart transplant in a pediatric patient. In subsequent years, HTx was performed in increasingly younger patients. In 1998, a heart transplant program was initiated in the youngest children (R. Przybylski, M. Zembala, B. Chodór). In 2008, HTx was performed in 2 infants at age of 9 and 10 months (R. Przybylski, Sz. Pawlak). In 2010, 5th the youngest (6-month-old) infant was transplanted due to severe HF in the course of DCM. Currently in Poland there is one center performing heart transplants in children: the Silesian Center for Heart Diseases in Zabrze. In the time period between years 2010 and 2021, 1333 heart transplants were performed in Poland, of which 609 (45.7%) of them in our Center and 75 of them were pediatric patients. Pediatric heart transplantations in our country remain low, about 6.9% of all heart transplants. The average number of HTx performed per year is 73 in adults and 7 in children in the last decade (2012–2021) in Poland [15]. The number of potential donors remains stable from many years, but still not efficient.

METHODS

Study group

Between 1988 and 2021 in the Silesian Center for Heart Diseases in Zabrze (formerly the

Provincial Center of Cardiology in Zabrze) 122 pediatric cardiac transplantations were performed: n = 30 in the first time period before year 2001, n = 31 in the second period (2002–2011) and n = 61 in the third period (2012–2021). The median age of the patients for the whole group was 12.3 (8.0–14.7) and in the individual periods: period I 13.3 (6.4–14.8), period II 12.7 (8.9–16.1), period III 11.5 (8.0–14.5). The age of the patients ranged from 6 months to 17 years and 10 months. The main indication for HTx in the time period between 2002 and 2021 (n = 92) was severe HF as a consequence of cardiomyopathy (n = 66, 71.7 %). In 25 recipients (27.2%) severe HF resulted from a congenital heart defect. The primary and post-inflammatory dilated cardiomyopathy was the most common indication (n = 59; 57.6%), hypertrophic cardiomyopathy (n = 13; 14.1%), restrictive cardiomyopathy (n = 10; 10.9%), arrhythmogenic ventricular cardiomyopathy (n = 1; 1.1%) and heart failure after oncological treatment (n = 1; 1.1%) caused heart failure requiring HTx. In the group of recipients with failing Fontan circulation HTx was performed in 5 children (5.4%). The endpoint of the study was the time when medical follow-up was completed or the patient died. The death was confirmed by the personal identification number database. It was retrospective study and institutional review board, ethics committee and patients written informed consent was not required.

Induction and immunosuppression

From 2006 to August 2014, basiliximab (Simulect), a chimeric human-mouse monoclonal antibody administered on day 0 and day 5 after HTx was used as the induction of immunosuppression as a standard procedure until company recommendation withdrawal. Triple-drug immunosuppressive therapy included the administration of methylprednisolone infusion in OR before reperfusion. The infusions were continued for 5 days and then changed to the oral form of prednisone. All recipients were treated with cyclosporine A (CyA) and mycophenolate mofetil (MMF) intravenously in 24 hours after Htx. After beginning of oral feeding, they were switched to oral forms of the drugs under the control of serum drug levels measured regularly (Table 1). Until 2006 CyA has been changed to tacrolimus (TAC).

Rejections

Rejection assessment was based on the endomyocardial biopsies (EBM). Full EBM protocol is shown in Table 2. EBM was performed through puncturing a peripheral vein: internal jugular or femoral vein using the Seldinger method. After assessing the pressure in right atrium and right ventricle, 5 to 10 fragments of myocardium were collected from the interventricular

septum. The myocardial fragments were fixed with 4% formalin and then stained with hematoxylin and eosin (HE) according to the standard protocol. Specimens were evaluated for the presence of acute cellular rejection (ACR) using the ISHLT 1995 classification (Table 3) [16, 17].

Rejection episodes were treated with 3-day use of methylprednisolone infusions and enlarged in MMF and TAC dosages. In the group of patients under 5 years of age, single or no EBM were performed (n = 12; 13%). In that cases, rejection screening was based on echocardiography evaluation and blood levels of biochemical markers: N-terminal prohormone of brain natriuretic peptide (NT-pro BNP), highly-sensitive troponin T, creatine kinase (CK-MB) and lactate dehydrogenase (LDH).

Statistical analysis

Data were presented as median with interquartile range for quantitative variables with other than normal distribution and mean SD for variables with normal distribution. Number of cases with percent were presented for qualitative ones. Test for two proportions was used to assess significance of differences between percentages. Shapiro Wilk test was used for normality assumption check

The Kaplan-Meier curves displayed the estimated survival probability. Differences in survival between groups were estimated using Mantel test for more than two groups. Statistical analysis was performed using the statistical package SOFA Statistic (open source AGPL3 license). Survival analysis was performed using R language in Rstudio Environment (RStudio Team (2020). RStudio: Integrated Development for R. RStudio, PBC, Boston, MA URL <http://www.rstudio.com/>) with additional packages: `survminer` and `survarium` (<https://cran.r-project.org/package=survminer>, <https://cran.r-project.org/package=survarium>). 5-year survival *P*-value <0.05 was considered statistically significant.

RESULTS

1-, 5- and 10-year survival rate between 1988 and 2001 were 53%, 53% and 50%, respectively. 1-, 5- and 10-year survival rate between 2002 and 2011 was 97%, 90% and 87%; between 2012 and 2021 1-year observation with survival rate 92% average. Median survival time in the years 2002–2011 was 9.2 (0.03–22.3) years, and 2012–2021 was 11.6 (10.2–13,7). Median survival was not analyzed in the years 2012–2021 because not all of the patients reached the 10-year observation follow-up. The main cause of mortality both in early and in late period after transplantation was graft failure (n = 5, 6.4% and n = 5, 6.4%, respectively).

In the study group, primary graft failure was the cause of 57% of hospital deaths. In two cases (2.5%) the cause of mortality was post-transplant lymphoproliferative disorder (PTLD). Distribution of HTx indications, characteristics of the study group, survival curve and the number of HTx performed were presented in [Table 4](#) and [Figures 1–4](#).

In 2010, the program of mechanical circulatory support (MCS) in children was initiated in SCCS in patients diagnosed with severe HF. Up to date 45 implantations of MSC have been performed with the use of the extracorporeal pulsatile systems of Polish (POLCAS, currently ReligaHeart EXT — 2 implantations) and German (Berlin Heart EXCOR — 40 implantations) production. There were also three implantations of the completely implantable heart assist system (Berlin Heart INCOR). MSC was used as a bridge to transplantation in 20 patients (18%) including 2 from another Center. 1- and 5-year survival was 92.6% each and there was no difference in survival between the two groups ($P = 0.11$).

DISCUSSION

Advances in surgical and anesthetic techniques, new immunosuppressive drugs, and thus new post-transplantation protocols, have significantly impact on the survival time of pediatric patients after heart transplantation. The observed survival times of our study group, in different eras, are comparable to those from the most experienced foreign centers. Mean survival time for children who underwent HTx at the age <1 year of age is 20.1 (SD, 0.8) years; at age 1–5 years is 17.2 (SD, 7.1); at age 6–10 years is 13.9 (SD, 1.8) and at age 11–17 years is 12.4 (SD, 6.8) years. 1-, 5- and 10-year survival rate is slightly better in the group of patients with cardiomyopathy, compared to patients with congenital heart disease as an indication for HTx (91.5% vs. 79.0%, 80.4% vs. 70% and 76.2% vs. 66.1%, respectively) [11, 12]. In the observed group the survival rate was: 89.3% vs. 85.2%; 87.5% vs. 76.7% and 84.2% vs. 62.7% respectively. The population of children supported with MSC before HTx also increases. In this group of patients there is a survival rate difference depending on the type of MCS. The longer survival time is observed in the group of patients on pulsatile extracorporeal ventricular assist devices (VAD) or total artificial hearts (TAH) in comparison to the group in which extracorporeal membrane oxygenation (ECMO) was used before HTx (1-year survival, respectively 91.7% vs. 66.1%). Among pediatric patients who underwent HTx after MCS in SCCS ($n = 20$; 18%), 1- and 5-year survival rates were 93.7% with no statistical significances ($P > 0.05$), respectively. The immunosuppressive induction protocol with the use of steroids and calcineurin inhibitors also had an impact on long-term survival. The occurrence of episodes of rejection significantly affects long term survival although the

1-year survival of patients who experienced heart rejection versus patients who did not is comparable (81.6% vs. 89.8%); the 5- and 10-year survival rates are significantly different: 70.1% vs. 79.3% respectively. In 8.1% to 21.4% of patients, the first episode of rejection occurs in the first year after transplantation [11, 12]. In almost 15% patients the treated rejection occurs in the first year after HTx, less frequently in patients who did not receive any induction and TAC has been used as immunosuppressive therapy regardless of age. In recipients with TAC treatment and no induction, rejection occurs in 14.6% of patients compared to group with TAC treatment and induction, CyA treatment and induction and CyA treatment and no induction (17.7%; 26.0% and 26.9% respectively) [11, 12]. In our study group rejection episodes requiring additional medical treatment occurred more frequently than in the ISHLT registry database. In the group of patients without MSC prior to HTx rejection was confirmed in 33.3% of patients comparing to group with MCS- 38.5%. The difference was not significant ($P = 0.74$). The development of CAV affects approximately 16% of infants who have HTx, 26% children at age 1–5, 27% at age 6–10 and 37% at age 11-17. This risk of CAV depends not on the type of induction and immunosuppressive protocols used, but on the donor age, the weight of the recipient and need of retransplantation. The higher risk of CAV affects patients with higher levels of circulating antibodies (PRA-panel reactive antibody) at the time of transplantation [11, 12]. The diagnosis of CAV limits the 1- and 3-year survival to 66%–77% and 52-60% respectively. Cytomegalovirus (CMV) reinfection after HTx is associated with increased morbidity and mortality in solid organ recipients. CMV reinfection has been show to play role in graft failure, acute rejection, development of CAV and post-transplant limfoproliferative disease (PTLD) [12, 18]. It occurs in the first two months after HTx, mostly in seronegative CMV recipients who receive seropositive donors organ. In our study group CMV reinfection occurred in 2.45% ($n = 3$) of patients transplanted between 2008 and 2021, despite used prophylactic antiviral treatment with intravenous and oral valganciclovir until 100 days after HTx. Another posttransplant complication is neoplastic disease especially in pediatric recipient. Lymphomas originating from B-lymphocytes associated with Epstein-Barr virus (EBV) reinfection are the most frequently occurring malignancies. The risk of developing malignancies increases with time after HTx: 1.6%; 4.7% and 9.7% in 1, 5 and 10 years respectively. 15 years after HTx neoplastic proliferative lesions occur as much as in 17% of patients [11, 12]. In the study group, PTLT occurred in 3 (2.45%) patients, of which 2 of them died (1.64%).

SUMMARY

Cardiac transplantation in both adults and children remains the main method of treatment of end-stage heart failure, despite the development of artificial circulatory techniques, using both pulsatile and continuous flow pumps. Our results at both early and long-term posttransplant period, are comparable to those obtained in the most experienced foreign centers. An inadequate number of pediatric donors remains a problem related not only to local conditions, but mainly to the transplantation awareness of the society. In comparison to countries with a smaller population, such as the Czech Republic or Croatia, the organ donation rate in Poland remains low, amounting to 14.6 donors / 1 million inhabitants and varies between regions of the country. In 2017, there were 24.7 donors / 1 million inhabitants in the West Pomerania in Poland. In the same time period, there were only 5.2 donors / 1 million inhabitants in the Podkarpackie Region. In Croatia, the donation rate is 33.0 donors / 1 million inhabitants, in the Czech Republic there are 25.5 donors / 1 million inhabitants, and in the best functioning donation system in Spain, the rate is 46.9 donors / 1 million inhabitants [19]. The low rate of donations in Poland continues to be of concern to the national institution, including Poltransplant and is the main topic of not only social campaigns but also development programs for healthcare professionals.

In conclusion, heart transplantation is the effective treatment method of heart failure but still requires further research especially in area of early and noninvasive diagnosis of acute allograft rejection that influences the long term follow up. The EMB still remains the gold standard for the diagnosis of rejection in adults but it is not performed in small children. There are publications on the important possible role of cardiovascular magnetic resonance (CMR) to support acute cardiac allograft rejection as the alternative to EBM [20] but in the pediatric recipient population still meets technical limitation. Small children do not cooperate during the procedure especially in breath holding and they must be deeply anesthetized and often intubated. If the procedure of CMR would be simplified and shortened there is possibility to the implement to the standart protocol of evaluation in the pediatric population. But still the role of CMR remains to be confirmed in prospective multicenter studies.

Article information

Conflict of interest: None declared.

Funding: None.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the

publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

REFERENCES

1. Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and pathophysiology. *Circ Heart Fail.* 2009; 2(1): 63–70, doi: [10.1161/CIRCHEARTFAILURE.108.820217](https://doi.org/10.1161/CIRCHEARTFAILURE.108.820217), indexed in Pubmed: [19808316](https://pubmed.ncbi.nlm.nih.gov/19808316/).
2. Nandi D, Rossano JW. Epidemiology and cost of heart failure in children. *Cardiol Young.* 2015; 25(8): 1460–1468, doi: [10.1017/S1047951115002280](https://doi.org/10.1017/S1047951115002280), indexed in Pubmed: [26675591](https://pubmed.ncbi.nlm.nih.gov/26675591/).
3. Nugent AW, Daubeney PEF, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. *N Engl J Med.* 2003; 348(17): 1639–1646, doi: [10.1056/NEJMoa021737](https://doi.org/10.1056/NEJMoa021737), indexed in Pubmed: [12711738](https://pubmed.ncbi.nlm.nih.gov/12711738/).
4. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. *N Engl J Med.* 2003; 348(17): 1647–1655, doi: [10.1056/NEJMoa021715](https://doi.org/10.1056/NEJMoa021715), indexed in Pubmed: [12711739](https://pubmed.ncbi.nlm.nih.gov/12711739/).
5. Wilkinson JD, Landy DC, Colan SD, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. *Heart Fail Clin.* 2010; 6(4): 401–13, vii, doi: [10.1016/j.hfc.2010.05.002](https://doi.org/10.1016/j.hfc.2010.05.002), indexed in Pubmed: [20869642](https://pubmed.ncbi.nlm.nih.gov/20869642/).
6. LOWER RR, SHUMWAY NE. Studies on orthotopic homotransplantation of the canine heart. *Surg Forum.* 1960; 11: 18–19, indexed in Pubmed: [13763847](https://pubmed.ncbi.nlm.nih.gov/13763847/).
7. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. *S Afr Med J.* 1967; 41(48): 1271–1274, indexed in Pubmed: [4170370](https://pubmed.ncbi.nlm.nih.gov/4170370/).
8. Kantrowitz A, Haller J, Joos H, et al. Transplantation of the heart in an infant and an adult. *Am J Cardiol.* 1968; 22(6): 782–790, doi: [10.1016/0002-9149\(68\)90173-2](https://doi.org/10.1016/0002-9149(68)90173-2), indexed in Pubmed: [4880223](https://pubmed.ncbi.nlm.nih.gov/4880223/).
9. Reyes J, Mazariegos GV, Vivas CA, et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation. *Surg Gynecol Obstet.* 1980; 151(1): 17–26, indexed in Pubmed: [6992310](https://pubmed.ncbi.nlm.nih.gov/6992310/).
10. Griffith BP, Hardesty RL, Deeb GM, et al. Cardiac transplantation with cyclosporin A and prednisone. *Ann Surg.* 1982; 196(3): 324–329, doi: [10.1097/00000658-198209000-00011](https://doi.org/10.1097/00000658-198209000-00011), indexed in Pubmed: [7051996](https://pubmed.ncbi.nlm.nih.gov/7051996/).

11. Goldfarb SB, Benden C, Edwards LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Pediatric Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. *J Heart Lung Transplant*. 2015; 34(10): 1255–1263, doi: [10.1016/j.healun.2015.08.005](https://doi.org/10.1016/j.healun.2015.08.005), indexed in Pubmed: [26454739](https://pubmed.ncbi.nlm.nih.gov/26454739/).
12. Thrush PT, Hoffman TM. Pediatric heart transplantation-indications and outcomes in the current era. *J Thorac Dis*. 2014; 6(8): 1080–1096, doi: [10.3978/j.issn.2072-1439.2014.06.16](https://doi.org/10.3978/j.issn.2072-1439.2014.06.16), indexed in Pubmed: [25132975](https://pubmed.ncbi.nlm.nih.gov/25132975/).
13. Berg A. Pediatric heart transplantation: a clinical overview. *Crit Care Nurs Q*. 2002; 25(3): 79–87, doi: [10.1097/00002727-200211000-00010](https://doi.org/10.1097/00002727-200211000-00010), indexed in Pubmed: [12450162](https://pubmed.ncbi.nlm.nih.gov/12450162/).
14. Rybínski K, Moll J, Stengert K, et al. [Preparatory work preceding the performance of heart transplantation: experimental, clinical and organizational]. *Pol Przegl Chir*. 1970; 42(2): 159–165, indexed in Pubmed: [4908983](https://pubmed.ncbi.nlm.nih.gov/4908983/).
15. Poltransplant Information Bulletin [in Polish]. 2021; 1(30): Available online: www.poltransplant.org.pl [Access: May 2022].
16. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant*. 2005; 24(11): 1710–1720, doi: [10.1016/j.healun.2005.03.019](https://doi.org/10.1016/j.healun.2005.03.019), indexed in Pubmed: [16297770](https://pubmed.ncbi.nlm.nih.gov/16297770/).
17. Stewart S, Winters G, Fishbein M, et al. Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection. *J Heart Transplant*. 2005; 24(11): 1710–1720, doi: [10.1016/j.healun.2005.03.019](https://doi.org/10.1016/j.healun.2005.03.019).
18. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. *Curr Infect Dis Rep*. 2012; 14(6): 633–641, doi: [10.1007/s11908-012-0292-2](https://doi.org/10.1007/s11908-012-0292-2), indexed in Pubmed: [22992839](https://pubmed.ncbi.nlm.nih.gov/22992839/).
19. International Registry in Organ Donation and Transplantation, Preliminary Numbers 2017; www.irodat.org. 2018. [Accessed: July 2018].
20. Dorniak K, Stopczyńska I, van Heeswijk RB, et al. [New right bundle branch block after heart transplant as sign of subclinical rejection]. *Kardiol Pol*. 2016; 74(3): 301–343, doi: [10.5603/KP.2016.0031](https://doi.org/10.5603/KP.2016.0031), indexed in Pubmed: [27004545](https://pubmed.ncbi.nlm.nih.gov/27004545/).

Table 1. Immunosuppressive drugs levels

DRUG	0–6 MONTHS	6–10 MONTHS	>12 MONTHS
Cyclosporine A (CyA)	200–300 ng/ml	150–200 ng/ml	100–150 ng/ml
Mycophenolate mofetil (MMF)	1.5–2.0 ng/ml	1.5–2.0 ng/ml	1.5–2.0 ng/ml
Tacrolimus (TAC)	10–15 ng/ml	10–12 ng/ml	8–10 ng/ml

Table 2. EBM protocol

DAYS AFTER HTX	
0–30	4 EBM every 7 days
31–60	2 EBM every 14 days
61–180	1 EBM every month
181–270	1 EBM
271–360	1 EBM
720	1 EBM with coronarography
Additional EBM	3–5 days after rejection treatment

Abbreviations: EBM, endomyocardial biopsies

Table 3. Comparison of the ISHLT 2004 and 1995 standardized EBM grade of Acute Cellular Rejection (ACR) [16, 17]

ISHLT 2004		ISHLT 1995	
GRADE	DESCRIPTION	GRADE	DESCRIPTION
0R	No rejection	0	No rejection
1R, mild	Interstitial and/or perivascular infiltrate with at least one focus of myocyte damage	1, mild	
		A – focal	Focal perivascular and/or interstitial infiltrate without myocyte damage

		B – diffuse	Diffuse infiltrate without myocyte damage
		2, moderate (focal) diffuse	One focus infiltrate with associated myocyte damage
2R, moderate	Two or more foci of infiltrate with associated myocyte damage	3, moderate	
		A – focal	Multifocal infiltrate with myocyte damage
3R, severe	Diffuse infiltrate with multifocal damage and/or edema and/or hemorrhage and/or vasculitis	B – diffuse	Diffuse infiltrate with myocyte damage
		4, severe	Diffuse, polimorphous infiltrate with extensive myocyte damage and/or edema and/or hemorrhage and/or vasculitis

Abbreviations: EBM, endomyocardial biopsies; ISHLT, International Society for Heart and Lung Transplantation

Table 4. Demographic characteristics of the recipients

GENDER			
		MALE	FEMALE
n		67	55
%		54.9	55.1
AGE OF HTX, years			
median (IQR)	12.3 (8.0–14.7)	14.0 (10.4–15.8)	10.2 (6.2–13.4)
min	0.54	0.54	0.76
max	17.82	17.82	17.41
WEIGHT, kg			

median (IQR)	38.9 (24.0–53.8)	44.6 (29.0–57.0)	30.0 (22.0–46.0)
Min	6.00	6.00	11.00
max	110.00	110.00	66.00
GROWTH, cm			
median (IQR)	147 (131–165)	152 (133–170)	138 (122–159)
min	65.0	65.0	84.0
max	195.0	195.0	170.0

Abbtrviations: HTx, heart transplantation




Figure 1. Indications for heart transplant in the Silesian Center for Heart Diseases in Zabrze
 Abbreviations: DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HTx, heart transplantation; RCM, restrictive cardiomyopathy; CHD, congenital heart defect




Figure 2. Number of pediatric heart transplant in the Silesian Center for Heart Diseases in Zabrze by year




Figure 3. Kaplan-Meier survival curve after pediatric heart transplant in the Silesian Center for Heart Diseases in Zabrze. I 1988–2001; II 2002–2011; III 2012–2021